What is Sunitinib Malate Market Scope?
Sunitinib is a small molecule, oral, multi-targeting receptor tyrosine kinase (RTK) inhibitor that was hereby approved by the FDA on January 26, 2006, for the purpose of treatment of renal cell carcinoma (RCC) as well as imatinib-resistant gastrointestinal stromal tumors (GIST) that sunitinib was first cancer drug that was approved for two different indications at the same time. Sunitinib is approved for the treatment of metastatic RCC. Sutent (sunitinib) is an expensive drug that targets proteins in cancer cells and prevents the cancer cells from growing. It is used to treat specific tumors of the digestive tract called GIST, advanced kidney cancer, and certain neuroendocrine tumors of the pancreas. It is less popular than similar drugs. There is currently no generic alternative to Sutent. Sunitinib malate is also offered as part of the Tocriscreen 2.0 Max, Tocriscreen Kinase Inhibitor Library, and Tocriscreen FDA-approved medicines.
The Sunitinib Malate market study is being classified, by Application (Kidney Cancer, Pancreas Cancer and Intestinal Cancer) and major geographies with country level break-up.
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies.
Pfizer (United States), PV Pharma (India) and Taj Pharma Group (India) are some of the key players profiled in the study.
Analyst at AMA have segmented the market study of Global Sunitinib Malate market by Type, Application and Region.
On the basis of geography, the market of Sunitinib Malate has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Based on these studies, Sunitinib received regulatory approval from the US Food and Drug Administration (US FDA) in 2007 and full marketing authorization from the European Medicines Agency (EMA). It continues to be recommended as the first-line treatment option for advanced or metastatic predominantly clear cell RCC in patients with good, moderate, and low-risk disease.
Influencing Market Trend
- Increasing Prevalence of Kidney Cancer
- Changes in the Medical Practices
- The increasing adoption of advanced therapy techniques
- Increase in the Consumption of Alcohol and Tobacco
- Changes in Lifestyle
- High Adoption of Premium-Priced Drugs
- Growing Geriatric Population
- Enhancement in Healthcare Expenditure in Developed Regions
- Increased R&D Expenditure of Pharmaceutical Companies
- Patent Expiry of Various Major Drugs
- High Cost of Sunitinib Drugs
- Lack of Awareness among People in Developing Countries
Key Target AudienceManufacturers of Sunitinib Malate, Suppliers and Distributors of Sunitinib Malate, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.